Loading patent…
AssigneeJong-Baeck Lim
InventorsJong-Baeck Lim, Jae-Il Choi, Hye Won Chung
Estimating the term…
The present invention relates to a composition for diagnosing resistance to a combination of ECF (Epirubicin, Cisplatin and 5-Fluorouracil; ECF), which is used for the treatment of gastric cancer, and a diagnostic kit comprising the same. In order to solve a problem that cancer recurrence and drug resistance occur due to an increase in tumor initiating cells (TICs) after treatment with a drug belonging to the ECF family, NINJ2 may be inhibited by early detection of resistance appearance, thereby suppressing the recurrence of gastric cancer and treating resistance to the drugs.
A method for diagnosing anticancer drug resistance, comprising measuring an expression level of NINJ2 (nerve injury-induced protein 2;
7-12. (canceled)
A method for preventing or treating cancer, comprising a step of administering an effective amount of an agent to a subject in need thereof, wherein the agent is for reducing an activity or expression level of NINJ2 (nerve injury-induced protein 2;
(canceled)
A method for treating anticancer drug resistance or enhancing anticancer drug sensitivity, comprising a step of administering an effective amount of an agent to a subject in need thereof, wherein the agent is for reducing an activity or expression level of NINJ2 (nerve injury-induced protein 2;
22-28. (canceled)
A method for screening a drug for treating anticancer drug resistance, comprising:
31-36. (canceled)
Dependencies are inferred from the claim text.